GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Cyclically Adjusted Revenue per Share

Intercept Pharmaceuticals (Intercept Pharmaceuticals) Cyclically Adjusted Revenue per Share : $5.87 (As of Sep. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Intercept Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Intercept Pharmaceuticals's adjusted revenue per share for the three months ended in Sep. 2023 was $2.125. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $5.87 for the trailing ten years ended in Sep. 2023.

During the past 12 months, Intercept Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 19.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-05), Intercept Pharmaceuticals's current stock price is $19.00. Intercept Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was $5.87. Intercept Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 3.24.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Intercept Pharmaceuticals was 11.22. The lowest was 1.86. And the median was 3.74.


Intercept Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Intercept Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Intercept Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 3.14 4.05 5.11

Intercept Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.93 5.11 5.35 5.61 5.87

Competitive Comparison of Intercept Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Intercept Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intercept Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Intercept Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Intercept Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=2.125/129.8595*129.8595
=2.125

Current CPI (Sep. 2023) = 129.8595.

Intercept Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.021 98.326 0.028
201403 0.021 99.695 0.027
201406 0.020 100.560 0.026
201409 0.021 100.428 0.027
201412 0.021 99.070 0.028
201503 0.065 99.621 0.085
201506 0.019 100.684 0.025
201509 0.018 100.392 0.023
201512 0.018 99.792 0.023
201603 0.018 100.470 0.023
201606 0.224 101.688 0.286
201609 0.209 101.861 0.266
201612 0.557 101.863 0.710
201703 0.844 102.862 1.066
201706 1.234 103.349 1.551
201709 1.647 104.136 2.054
201712 1.498 104.011 1.870
201803 1.421 105.290 1.753
201806 1.492 106.317 1.822
201809 1.587 106.507 1.935
201812 1.795 105.998 2.199
201903 1.756 107.251 2.126
201906 2.117 108.070 2.544
201909 1.894 108.329 2.270
201912 2.180 108.420 2.611
202003 2.231 108.902 2.660
202006 2.344 108.767 2.799
202009 2.411 109.815 2.851
202012 0.138 109.897 0.163
202103 2.464 111.754 2.863
202106 2.055 114.631 2.328
202109 2.100 115.734 2.356
202112 2.323 117.630 2.565
202203 1.992 121.301 2.133
202206 2.412 125.017 2.505
202209 2.263 125.227 2.347
202212 1.858 125.222 1.927
202303 1.631 127.348 1.663
202306 2.006 128.729 2.024
202309 2.125 129.860 2.125

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Intercept Pharmaceuticals  (NAS:ICPT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Intercept Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=19.00/5.87
=3.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Intercept Pharmaceuticals was 11.22. The lowest was 1.86. And the median was 3.74.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Intercept Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Intercept Pharmaceuticals (Intercept Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
N/A
Address
305 Madison Avenue, Morristown, NJ, USA, 07960
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Executives
Andrew Saik officer: EVP & Chief Financial Officer 640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey officer: President, R&D and CMO 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia officer: Chief Accounting Officer C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
Lisa Defrancesco officer: SVP, IR & Corp. Affairs C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson officer: EVP & Chief Commercial Officer 2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg officer: General Counsel and Secretary 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball officer: Chief Quality Officer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sandip Kapadia officer: CFO and Treasurer 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
Jason Campagna officer: Chief Medical Officer C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Paolo Fundaro director, 10 percent owner C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Francesco Micheli 10 percent owner C/O GENEXTRA S.P.A., VIA G. DE GRASSI, 11, MILAN L6 20124
Genextra S.p.a. 10 percent owner VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener director 900 FIFTH AVENUE, #8C, NEW YORK NY 10021

Intercept Pharmaceuticals (Intercept Pharmaceuticals) Headlines

From GuruFocus